Hematologic toxicity frequently complicates chimeric antigen receptor (CAR) T-cell therapy, resulting in significant morbidity and mortality. In an effort to standardize reporting, the European Hematology Association (EHA) and European Society of Blood and Marrow Transplantation (EBMT) devised the immune effector cell-associated hematotoxicity (ICAHT) grading system, distinguishing between early (day 0-30) and late (after day +30) events based on neutropenia depth and duration. However, manual implementation of ICAHT grading criteria is time-consuming and susceptible to subjectivity and error. To address these challenges, we introduce a novel computational approach, utilizing the R programming language, to automate early and late ICAHT grading. Given the complexities of early ICAHT grading, we benchmarked our approach both manually and computationally in two independent cohorts totaling 1251 patients. Our computational approach offers significant implications by streamlining grading processes, reducing manual time and effort, and promoting standardization across varied clinical settings. We provide this tool to the scientific community alongside a comprehensive implementation guide, fostering its widespread adoption and enhancing reporting consistency for ICAHT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380036 | PMC |
| http://dx.doi.org/10.1038/s41409-024-02278-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs).
Blood Adv
December 2024
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States.
Article Synopsis
- - Immune effector cell-associated hematotoxicity (ICAHT) significantly affects patients undergoing CAR T-cell therapy, and the factors linked to severe forms of it are not well understood.
- - Researchers identified key pre-infusion and post-infusion factors that predict early severe ICAHT in a study involving 691 patients; these included disease type, blood counts, inflammatory and coagulopathy markers.
- - Two predictive models (eIPMPre and eIPMPost) were developed and validated, showing strong accuracy in predicting severe ICAHT, with the post-infusion model being particularly effective; an online tool for individualized predictions is available for use.
Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.
J Immunother Cancer
November 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
B-cell maturation antigen(BCMA)-directed chimeric antigen receptor (CAR)-T-cell therapy has significantly improved the treatment of relapsed or refractory multiple myeloma (MM). Nevertheless, the uncommon phenomenon of biphasic CAR-T cell expansion in vivo and its related severe toxicities have not been methodically described and studied. Herein, we report a case of patients with MM who experienced two CAR-T cell expansion peaks and subsequently developed multiple severe toxicities following BCMA CAR-T cell infusion.
View Article and Find Full Text PDFDevelopment of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.
Blood
November 2024
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, United States.
Article Synopsis
- - Immune effector cell-associated hematotoxicity (ICAHT) is a common toxicity linked to CAR T-cell therapy, notably affecting patients with various lymphomas and multiple myeloma, but has not been previously studied in B-cell acute lymphoblastic leukemia (B-ALL).
- - In a study involving 156 young patients with relapsed/refractory B-ALL, severe neutropenia was observed for a median of 13 days, with over half experiencing significant ICAHT, which indicated the need for better predictive models for this condition.
- - The researchers developed the ALL-Hematotox (ALL-HT) score, improving on existing models by incorporating bone marrow disease burden, which accurately predicted severe neutrop
Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients.
J Clin Med
August 2024
Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Article Synopsis
- Immune effector cell-associated hematotoxicity (ICAHT) is a common complication in CAR-T cell therapy, leading to significant thrombocytopenia in about one-third of patients, often necessitating platelet transfusions.
- Eltrombopag, a thrombopoietin receptor agonist, was evaluated in a study involving 38 patients from 10 hospitals in Spain who developed platelet transfusion dependence after CAR-T treatment.
- The results showed that 76.3% of patients achieved platelet transfusion independence after using eltrombopag, with additional improvements noted in neutrophil and red blood cell counts, and no serious side effects reported.
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity.
Bone Marrow Transplant
July 2024
Fred Hutchinson Cancer Center, Seattle, WA, USA.
Hematologic toxicity frequently complicates chimeric antigen receptor (CAR) T-cell therapy, resulting in significant morbidity and mortality. In an effort to standardize reporting, the European Hematology Association (EHA) and European Society of Blood and Marrow Transplantation (EBMT) devised the immune effector cell-associated hematotoxicity (ICAHT) grading system, distinguishing between early (day 0-30) and late (after day +30) events based on neutropenia depth and duration. However, manual implementation of ICAHT grading criteria is time-consuming and susceptible to subjectivity and error.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!